Elan to 'release' $1bn from Tysabri pay-off
This article was originally published in Scrip
Executive Summary
Elan will spend $1 billion of the $3.25 billion one-off payment it is receiving from Biogen Idec for the return of rights to the blockbuster multiple sclerosis drug Tysabri to buy back around a 16% stake in the Irish company.